Healthcare utilization patterns before and after a long COVID diagnosis: a case-control study.

Publication date: Feb 10, 2025

Documenting Long COVID cases has been challenging partly due to the lack of population-level data and uncertain diagnostic criteria, hindering the ability to ascertain healthcare utilization patterns over time. The objective of this study is to examine the characteristics and healthcare utilization patterns of Long COVID patients in Colorado pre- and post-diagnosis compared to controls. Retrospective, longitudinal case-control study using a 100% sample of Colorado’s All-Payer Claims Database. The sample includes individuals 18 or older diagnosed with Long COVID between October 1, 2021, and August 1, 2022, with patients followed until August 2023. Long COVID was identified using the International Classification of Diseases, 10th Revision, U09. 9 code in medical insurance claims. Analysis of healthcare utilization required one year of continuous enrollment before and after diagnosis. Controls were matched 2:1 on age group, sex, payer, and index month to account for contemporaneous trends in utilization. 26,358 individuals were ever diagnosed with Long COVID, resulting in a claims-based prevalence of 674 per 100,000 during the study period (population 3,906,402 individuals). Of these, 12,698 individuals had continuous enrollment and a Long COVID diagnosis: mean (SD) age, 59. 0 (17. 1); 65. 3% female; 60. 1% white; 83. 0% residing in urban areas. The Long COVID sample was matched with 25,376 controls. Before diagnosis, 17% of Long COVID patients were hospitalized at least once, and 40% visited an emergency department on at least one occasion. Within the year following diagnosis, utilization of acute healthcare services significantly decreased relative to controls: hospitalizations, -6. 1percentage points (p. p.), emergency department visits, -7. 7 p. p., whereas outpatient services and medications increased: office visits, 3. 6 p. p.; specialist office visits, 4. 7 p. p.; and 5. 2 new medications, (controls: 2. 8). Changes in diagnoses of some conditions (e. g., metastatic carcinomas and lung cancer) were similar between groups. Long COVID patients increased outpatient healthcare utilization following a diagnosis, switching from acute care settings. The change in service settings among this population suggests that diagnosis could lead to better patient management. Healthcare utilization among these patients is high, underscoring the need to understand the Long COVID burden on healthcare systems with population-level data.

Open Access PDF

Concepts Keywords
August Cancer
Carcinomas Healthcare utilization
Colorado Long COVID
PASC
PCC

Semantics

Type Source Name
disease MESH long COVID
disease MESH emergency
disease MESH carcinomas
disease MESH lung cancer
drug DRUGBANK Tropicamide
pathway REACTOME Reproduction
drug DRUGBANK Factor IX Complex (Human)
disease MESH SARS CoV 2 infection
drug DRUGBANK Ilex paraguariensis leaf
disease IDO process
disease MESH infection
disease MESH chronic condition
disease MESH tachycardia
disease MESH Sequelae
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Trestolone
disease MESH Retirement
disease MESH tics
disease MESH unemployment
disease MESH Comorbidity
disease MESH postural orthostatic tachycardia syndrome
disease MESH myalgic encephalomyelitis
drug DRUGBANK Coenzyme M
disease MESH COPD
disease MESH infectious diseases
disease IDO blood
disease MESH musculoskeletal pain
disease MESH low back pain
disease MESH sleep wake disorders
disease MESH pneumonia
disease MESH respiratory failure
disease MESH mental disorders
disease MESH obesity
disease MESH chest pain
drug DRUGBANK Prednisone
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Amoxicillin
drug DRUGBANK Salbutamol
drug DRUGBANK Azithromycin
drug DRUGBANK Ondansetron
drug DRUGBANK Benzonatate
drug DRUGBANK Gabapentin
drug DRUGBANK Oxycodone
drug DRUGBANK Omeprazole
drug DRUGBANK Atorvastatin
drug DRUGBANK Doxycycline
drug DRUGBANK Cephalexin
drug DRUGBANK Fluticasone
drug DRUGBANK Sulfamethoxazole
drug DRUGBANK Nitrofurantoin
drug DRUGBANK Clindamycin
drug DRUGBANK Ciprofloxacin
drug DRUGBANK Mupirocin
drug DRUGBANK Metronidazole
drug DRUGBANK Hydrocodone
drug DRUGBANK Cyclobenzaprine
drug DRUGBANK Tramadol
drug DRUGBANK Ibuprofen
drug DRUGBANK Meloxicam
drug DRUGBANK Diclofenac
drug DRUGBANK Methocarbamol
drug DRUGBANK Naproxen
drug DRUGBANK Iron
disease MESH asthma
pathway KEGG Asthma
disease MESH causality
disease IDO virulence
disease IDO symptom
disease MESH dementia
disease MESH fibromyalgia
drug DRUGBANK Etoperidone
disease MESH Viral Infection
disease MESH Cancer
drug DRUGBANK (S)-Des-Me-Ampa
disease IDO acute infection
drug DRUGBANK Carboxyamidotriazole
disease IDO quality
drug DRUGBANK Tolbutamide
disease MESH Alzheimer’s disease

Original Article

(Visited 1 times, 1 visits today)